Information Provided By: 
Fly News Breaks for May 22, 2015
RLYP, ZSPH
May 22, 2015 | 08:01 EDT
JPMorgan analyst Cory Kasimov raised his price target for shares of ZS Pharma (ZSPH) to $75 from $57 following the stock's 45% rise in May. Kasimov believes treating high blood potassium represents a multi billion dollar opportunity in the U.S. alone, and he thinks ZS Pharma's ZS-9 has potentially important advantages over Relypsa's (RLYP) patiromer. He find ZS's current valuation as "highly compelling" and reiterates an Overweight rating on the name. The biopharmaceutical company closed yesterday up $1.97 to $56.50.
News For ZSPH;RLYP From the Last 2 Days
There are no results for your query ZSPH;RLYP
